NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Evotec SE EVO
6 fiscal years on record · EUR · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
€797.0M
▲ 2.0% vs FY2023
EPS · FY24
€-1.11
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-18.9%
Net margin · FY24
-24.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 797.0M
Revenue, FY2024 · full 6-year series below
Revenue
Net income
The company lost 25 cents on every revenue dollar this year.
Per share
EUR -1.11
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-18.9%
Return on equity, FY2024
ROE
Operating margin-17.9%
Net margin-24.6%
Return on assets-9.4%
Each EUR of equity lost 19 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+12.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+8.8%
+12.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.18B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 1.9B
total assets, end of FY2024
Total assetsEUR 1.9B
EquityEUR 952.5M
CashEUR 306.4M
Gross debtEUR 287.6M
Net debtEUR -18.8M
Current ratio1.98×
The company holds more cash than debt.
History
6 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2024
2023
2022
2021
2020
2019
Revenue €B
0.8
0.8
0.8
0.6
0.5
0.4
Operating income €B
−0.1
−0.0
0.0
0.0
0.0
0.1
EBITDA €B
·
·
·
·
·
·
Income tax €B
0.0
0.0
0.0
0.0
0.0
0.0
Net income €B
−0.2
−0.1
−0.2
0.2
0.0
0.0
EPS, diluted €
−1.11
−0.47
−0.99
1.30
0.04
0.25
Dividend / sh €
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−18.9
−7.3
−13.7
20.5
0.9
·
Shares out B
0.18
0.18
0.18
0.18
0.16
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed